Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma

Authors

  • Qing-Jiang Yu Department of Hepatobiliary Surgery, First Affiliated Hospital of Jiaxing University, Jiaxing 314000, China
  • Yi-Zhi Liang Department of Gastroenterology, Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, China
  • Xiao-Ping Mei Department of Hepatobiliary Surgery, First Affiliated Hospital of Jiaxing University, 1882, Zhonghuan South Road, Jiaxing 314000, China; E-mail: xipimeijx@163.com
  • Tai-Yong Fang Department of Gastroenterology, Second Affiliated Hospital, Fujian Medical University, 34, Zhongshan North Road, Quanzhou 362000, China; E-mail: fangtaiyong@126.com

DOI:

https://doi.org/10.17179/excli2020-2171

Keywords:

Tumor mutation burden (TMB), miRNA-gene interaction, liver hepatocellular carcinoma (LIHC), prognosis

Abstract

Tumor mutation burden (TMB) is associated with immunogenic responses and the survival of cancer patients. This study demonstrates how TMB levels impact the immune-related cells, genes, and miRNAs, and how miRNA/gene interactions respond to variations in the survival rate of patients with liver hepatocellular carcinoma (LIHC). LIHC patients were divided into two groups, either a low TMB (< median) or a high TMB (≥ median) group. We found that high TMB plays a positive role in immune-mediated infiltration, generating more CD4 T-cells and memory B cells. Among the 21 immune genes that altered significantly, only C9orf24 and CYP1A1 were expected to up-regulate in LIHC patients with high TMB. A total of 19 miRNAs, which regulate various functional pathways, were significantly altered in patients with LIHC. One of the miRNA/gene pair, hsa-miR-33a/ALDH1A3 was significantly associated with the survival rate of LIHC patients. Our results suggest that LIHC patients with high TMB can be treated more effectively with immunotherapy.

Downloads

Published

2020-06-22

How to Cite

Yu, Q.-J., Liang, Y.-Z., Mei, X.-P., & Fang, T.-Y. (2020). Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma. EXCLI Journal, 19, 861–871. https://doi.org/10.17179/excli2020-2171

Issue

Vol. 19 (2020)

Section

Original articles

License

Copyright (c) 2020 Qing-Jiang Yu, Yi-Zhi Liang, Xiao-Ping Mei, Tai-Yong Fang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).